A link between hypercholesterolemia and chronic lymphocytic leukemia.
The incidence of hypercholesterolemia and its possible relationship with clinical course were determined by reviewing the records of 231 consecutive patients presenting to a specialized Chronic Lymphocytic Leukemia (CLL) clinic. Evidence for elevated cholesterol was found in up to 174/231 patients (75%) based on existing use of statins (107 patients) or non-fasting low-density lipoprotein cholesterol levels greater than 2.5 mM. Excluding patients with 17p deletions, time to first treatment (TFT) was prolonged if patients were taking cholesterol-lowering statins (57.5 (IQR = 32, 77) vs 36 (IQR = 11, 100) months, p < 0.02). If patients were prescribed statins after being diagnosed with CLL, TFT was longer than if they were taking statins before the diagnosis. These observations suggest there is a high incidence of hypercholesterolemia in CLL patients and cholesterol-lowering may impact the disease course.
a Odette Cancer Centre and Sunnybrook Health Sciences Centre , Toronto , ON , Canada .|b Division of Hematology and Oncology, Department of Medicine , University of Toronto , Toronto , ON , Canada , and.
Signy
S
Chow
a Odette Cancer Centre and Sunnybrook Health Sciences Centre , Toronto , ON , Canada .|b Division of Hematology and Oncology, Department of Medicine , University of Toronto , Toronto , ON , Canada , and.
Rena
R
Buckstein
a Odette Cancer Centre and Sunnybrook Health Sciences Centre , Toronto , ON , Canada .|b Division of Hematology and Oncology, Department of Medicine , University of Toronto , Toronto , ON , Canada , and.|c Division of Molecular and Cellular Biology , Sunnybrook Research Institute, University of Toronto , Toronto , ON , Canada.
David E
DE
Spaner
D000368:Aged; D015415:Biomarkers; D008078:Cholesterol, LDL / Q000097:blood; D015331:Cohort Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology* / Q000378:metabolism; D015994:Incidence; D053208:Kaplan-Meier Estimate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000453:epidemiology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D016896:Treatment Outcome
D015415:Biomarkers; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
Chronic lymphocytic leukemia; HMG-CoA reductase inhibitor; cholesterol; inflammation; lipoprotein; signal transduction; statin